# Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

Study · id `cardio:ct-nct05226897` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05226897](<https://clinicaltrials.gov/study/NCT05226897>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05226897

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 256 participants.

## Technical summary

Registry record NCT05226897. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-12 (actual); primary completion 2022-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 256 participants (planned count; ClinicalTrials.gov record NCT05226897, source copy `cardio:ctgov-nct05226897-2022-06-01`, retrieved 2026-10-26)
- Started: 2021-07-12 (actual) (ClinicalTrials.gov record NCT05226897, source copy `cardio:ctgov-nct05226897-2022-06-01`, retrieved 2026-10-26)
- Primary completion: 2022-10-31 (anticipated) (ClinicalTrials.gov record NCT05226897, source copy `cardio:ctgov-nct05226897-2022-06-01`, retrieved 2026-10-26)
- Completion: 2023-06-26 (anticipated) (ClinicalTrials.gov record NCT05226897, source copy `cardio:ctgov-nct05226897-2022-06-01`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05226897, source copy `cardio:ctgov-nct05226897-2022-06-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05226897-2022-06-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
- Condition: Type 2 Diabetes
- Intervention (Drug): YYC405-T
- Intervention (Drug): Metformin≥1000mg
- Intervention (Drug): Dapagliflozin 10mg
- Intervention (Drug): YYC405-T placebo
- Lead sponsor: Yooyoung Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin (`cardio:pubmed-38425186`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 7413ea6cb85300e5af9f2b609ac3b054676973cbc112265a99a5ed516ff224fc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
